RetaCalc
Protocol library
SingleInvestigationalPhase 2Sourced

Cagrilintide

A long-acting amylin analogue under clinical investigation for weight management, with dose-ranging human evidence but no routine-use authorisation.

Evidence context, not a personal protocol

Quantities below reproduce study or label context. They do not assess suitability, product equivalence or individual risk.

Regimens studied

Adults with overweight or obesity without diabetes

Once-weekly dose-finding arms of 0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg and 4.5 mg with escalation every 2 weeks

Phase 2 research allocation over 26 weeks with placebo and liraglutide comparators.

View source

Evidence summary

The phase 2 dose-finding study evaluated several assigned doses and an active comparator. It was designed to characterise efficacy, tolerability and dose response under research monitoring.

Interpretation

Trial arms should not be converted into self-directed schedules. Ongoing development may change the selected formulation, regimen and regulatory conclusions.

Warnings and contraindications

Cagrilintide remains investigational and trial regimens are not prescribing guidance.
Gastrointestinal adverse events were common in the phase 2 study.